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AbstrAct
The Global Orthopaedic Registry (GLORY) has been 
designed to monitor a broad range of complications 
and outcomes that occur following total hip arthroplasty 
(THA) and total knee arthroplasty (TKA). GLORY provides 
global ‘‘real-world” data, in contrast to the data gener-
ated by the controlled conditions of clinical trials. 
    The results to date show an overall incidence of both 
in-hospital and post-discharge complications of approx-
imately 7% in THA patients and 8% in TKA patients. The 
most common in-hospital complications in THA patients 
are fractures (0.6%) and deep vein thrombosis (DVT) 
(0.6%), whereas in TKA patients DVT (1.4%) and cardiac 
events (0.8%) are most common. The most common 
post-discharge complications in both THA and TKA 
patients are reoperation due to bleeding, wound necro-
sis, wound infection, or other causes; and DVT. Bleeding 
complications were less common than other adverse 
events in both groups (in-hospital rates of 0.48% and 
0.83%, respectively). Functional outcomes improved 
after surgery in both groups, as expected. Younger 
patients and patients who had been discharged directly 
to their homes seemed to have the greatest improve-
ment in functional outcome after surgery. 
The Global Orthopaedic Registry (GLORY) has been designed not only to monitor practices in orthopedic surgery but also to provide insights into complications and functional outcomes 
resulting from such surgery.
Data on outcomes after total hip arthroplasty (THA) 
or total knee arthroplasty (TKA) have been collected 
from clinical trials that assess individual devices or 
from country-specific registries. The first registries to be 
established were the Swedish THA and TKA registries.1,2 
These, together with subsequent country-specific regis-
tries worldwide, have provided important information on 
the long-term outcomes following THA and TKA. Most 
registries focus on outcomes resulting from different types 
of implant and the factors that affect implant survival. As 
a result, they provide a valuable quality-improvement tool 
to identify inferior implants as early as possible,1,3 but they 
offer relatively little information about other complica-
tions and functional outcomes.
GLORY has been designed to monitor a broader range 
of complications and outcomes than those related solely to 
implant survival.4 As an international registry, it includes 
global, rather than country-specific or implant-specific, 
data. Data from GLORY can thus provide important 
insights into THA and TKA practices worldwide and also 
the incidence of different types of complications. Because 
of the worldwide nature of GLORY, some practice pat-
terns, such as the relatively high prescription rate of low-
molecular-weight heparin and the low rate  of aspirin use 
for prophylaxis of venous thromboembolism (VTE) may 
not be representative of a US-specific population. 
This paper reviews the incidence and nature of compli-
cations following THA or TKA as recorded in GLORY and 
compares these findings with those of previous studies.
Methods
GLORY is a multinational, observational study that has 
been designed to examine treatment practices in patients 
undergoing major joint replacement surgery. The meth-
odology has been described in full by Anderson and 
colleagues.5 The study was designed and is coordinated 
by the Center of Outcomes Research at the University of 
Massachusetts, USA, under the guidance of a Scientific 
Advisory Board. Full details of GLORY are available on 
the registry web site.4
A total of 156 surgeons have enrolled patients from 100 
university-affiliated or community hospitals in 13 coun-
tries worldwide. Participating surgeons enrolled 15,020 
patients who had undergone elective primary THA (6,695 
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patients) or TKA (8,325 patients) between June 2001 and 
December 2004; revision procedures were excluded. In-
hospital data were collected for all patients, and 70% of 
patients were followed up after 3 months and/or 12 months 
to collect data on post-discharge outcomes.  
Participating surgeons or trained study coordinators col-
lected data using standard case report forms, which were 
sent to the scientific coordinating center for entry into the 
database and for subsequent analysis. Data quality control 
was monitored using standardized query logic. Out-of-range 
or illogical responses were queried on a quarterly basis, and 
corrections were faxed to the scientific coordinating center.
Approval of the study was obtained from local ethics 
committees or institutional review boards, as required. 
When required by the Ethics Review Committee at each 
hospital, signed informed consent was obtained from 
patients prior to their enrollment. Chi-square or Fisher’s 
exact test was used to test for rate differences in different 
groups. Wilcoxon’s ranked sum test or analysis of variance 
was used to test group differences between continuous 
variables.
GenerAl coMplicAtions
Previous studies have identified a broad range of compli-
cations following THA6,7 or TKA.8 These include delayed 
wound healing or wound dehiscence; renal and urinary 
complications; cardiovascular complications, VTE includ-
ing deep vein thrombosis (DVT) and pulmonary embolism 
(PE), myocardial infarction, or bleeding; and pneumonia 
and other respiratory complications.
The data from GLORY show a similar spectrum of 
complications (Table I). The overall incidence of both in-
hospital and post-discharge complications was approxi-
mately 7% in THA patients and 8% in TKA patients. 
However, the nature of the recorded complications was 
similar in all countries and all types of hospitals. The 
incidence of in-hospital and post-discharge complica-
tions was similar in the United States and in the other 
participating countries in THA patients (P = .32 and .60 
for in-hospital and post-discharge, respectively), but was 
slightly higher in other participating countries than in 
the United States in TKA patients (P<.001 for both in-
hospital and post-discharge; Figure).
Table I. Incidence of Complications Occurring in Hospital and After Discharge in GLORY
                    In-Hospital            Additional Complications  
Complication                Complications              3 Months Post-Surgery
   THA (n = 6,695) TKA (n = 8,325) THA (n = 4,940) TKA (n = 5,550)
One or more complications 486 (7.3%)                 671(8.1%) 332 (6.7%)    445 (8.0%)
Fracture   41 (0.6%)   8 (0.1%)   19 (0.4%)   10 (0.2%)
Deep vein thrombosis   40 (0.6%)                113 (1.4%)   49 (1.0%)       38 (0.7%)
Dislocation   34 (0.5%)   3 (0.1%)   39 (0.8%)     3 (0.1%)
Nerve palsy           33 (0.5%) 14 (0.2%)   19 (0.4%)        11 (0.2%)
Wound infection     29 (0.4%) 35 (0.4%)   43 (0.9%)        94 (1.7%)
Reoperation   27 (0.4%) 42 (0.5%)   56 (1.1%)    126 (2.3%)
Bleeding—delayed discharge/  
   Major bleeding*   21 (0.3%) 26 (0.3%)     4 (0.1%)      8 (0.1%)
Cardiac events   29 (0.4%) 50 (0.8%)   10 (0.2%)    18 (0.3%)
Pneumonia   14 (0.2%) 29 (0.5%)        ND        ND
Pulmonary embolism     7 (0.1%) 23 (0.3%)     6 (0.1%)     6 (0.1%)
Death     9 (0.1%) 16 (0.2%)   16 (0.3%)     7 (0.1%)
Other**       236 (3.5%)                325 (3.9%) 149 (3.0%)    263 (4.7%)
* Bleeding defined as “Bleeding-delayed discharge’’ for in-hospital complications and defined as “Major bleeding’’ for additional complications 3 months post-surgery
** Unspecified.
Abbreviations: THA,  total hip arthroplasty; TKA, total knee arthroplasty; ND, no data.
Table II. Incidence of Bleeding in Hospital and 3 Months After Surgery
 
                             Additional Bleeding 
Bleeding Type              In-Hospital Bleeding         3 Months Post-Surgery  
   THA (n = 6,695) TKA (n = 8,325) THA (n = 4,940)  TKA (n = 5,550)
Bleeding necessitating reoperation   2 (0.03%)   9 (0.11%) 1 (0.02%)   3 (0.06%)
Bleeding-delayed discharge 21 (0.31%) 26 (0.31%) 0   0
Hematoma requiring evacuation   7 (0.10%) 25 (0.30%) 1 (0.02%)   4 (0.07%)
Epidural hematoma   1 (0.01%)   1 (0.01%) 0   0
Gastrointestinal bleeding   3 (0.06%) 15 (0.25%) 0   0
Other bleeding during surgery   2 (0.04%)   0 0   0
Major bleeding   0   0 4 (0.08%)   8 (0.14%)
Readmission due to bleeding   0   0 2 (0.04%)   1 (0.02%)
Any  32 (0.48%)* 69 (0.83%)* 8 (0.16%) 16 (0.29%)
* Significantly different, P = .01
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In THA patients, the most common in-hospital compli-
cations were fractures and DVT, both of which occurred 
in 0.6% of patients, whereas in TKA patients the most 
common in-hospital complications were DVT (1.4%) and 
cardiac events (0.8%). The most common post-discharge 
complications in both THA and TKA patients were reoper-
ation due to bleeding, wound necrosis, wound infection, or 
other causes (1.1% and 2.3%, respectively), wound infec-
tions (0.9% and 1.7%, respectively), and DVT (1.0% and 
0.7%, respectively). Some complications, such as myocar-
dial infarction and pneumonia, were uncommon in both 
groups, reflecting the fact that THA and TKA are elective 
procedures that are mainly performed in healthy patients.
The relatively low incidence of reoperations reported in 
GLORY is of interest, given the higher incidence reported 
in the Swedish hip and knee registries. As noted earlier, 
these focus largely on implant survival as a major outcome 
and document the reasons for reoperation or revision.1 
Of 229,031 primary THAs that were performed between 
1979 and 2003, reoperation was necessary in 26,111 
(11.4%).2 The most common reason for reoperation was 
aseptic loosening, which accounted for 60.6% of reop-
erations, followed by dislocation (10.7%), deep infection 
(8.3%), and fracture (6.8%).2 Among patients undergo-
ing knee arthroplasty (both TKA and unicompartmental 
arthroplasty), a total of 1,902 of 41,223 (4.6%) primary 
arthroplasties that were performed between 1988 and 1997 
had been revised by the end of this period.8 The principal 
reason for revision (including revisions of arthroplasties 
that were performed before 1988) was loosening, which 
accounted for 44% of procedures. Approximately 50% of 
revisions were performed within 4 years of the primary 
arthroplasty; in particular, revisions due to infection or 
patellar problems were more common during the first 45 
months than they were after the first 45 months.9 
The higher incidence of reoperations seen in the Swedish 
registry data, compared with the GLORY data, may reflect 
the shorter follow-up period in GLORY and the fact that 
since the time the Swedish registry was started (as early 
as 1979) practice has improved with type of implants, 
antibiotics, and so on. It is difficult to compare the rates of 
other complications in the Swedish and GLORY registries 
because GLORY reports all complications, whereas the 
Swedish registries report only those that lead to reopera-
tion. For example, DVT and cardiac events are relatively 
frequent complications in GLORY (Table I), whereas these 
tend to be unreported in the Swedish registries as they 
would not lead to revision.
A further registry-based study, which was conducted in 
Iceland, has reported markedly higher rates of dislocations 
(5%) and cardiac or cerebrovascular complications (3.1%) 
among THA patients than those reported in GLORY (Table 
I).10 The incidence of wound infections (0.5%) and VTE, 
including both DVT and PE (1.5%), in this study were 
comparable with those in GLORY. However, as with the 
Swedish registries, these data are country-specific and, 
moreover, relate to a smaller patient population (548), who 
received a single type of implant.
bleedinG 
Comparisons of bleeding rates in studies of THA and TKA 
patients are complicated because the definitions of clini-
cally important or major bleeding have varied considerably 
between trials.11 In GLORY, clinically important bleeding 
has been defined as “bleeding that is recorded by the sur-
geon as being outside the range of ‘typical expected levels’ 
of bleeding following THA/TKA, or bleeding that is cited 
as the cause of prolonged hospital stay.” Clinically impor-
tant bleeding included multiple types of bleeding (Table 
II), amongst others bleeding necessitating reoperation, 
bleeding-delayed discharge, and gastrointestinal bleeding. 
The incidence of such bleeding in GLORY was relatively 
Table III. Incidence of Bleeding 
(Major or Minor) in Relation to Use of 
Thromboprophylaxis 
   n (In-Hospital)   
   / n (In-Hospital   In-Hospital or
   or 3 Month   3 Month
   Post-Surgery  In-Hospital Post-Surgery
   Bleeding) Bleeding Bleeding
LMWH alone 9,241/5,858 65 (0.7%)* 45 (0.8%)
Warfarin alone 4,148/1,431 14 (0.3%)*   9 (0.6%)
Both    485/308   8 (1.7%)   6 (2.0%)
Neither 1,146/563 14 (1.2%) 10 (1.8%)
* Significantly different, P = .01
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Figure. Incidence of in-hospital and post-discharge compli-
cations following total hip arthroplasty and total knee arthro-
plasty in the United States (USA) and the other participating 
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low, both in THA patients (0.48% in hospital; 0.16% 3 
months after surgery) and in TKA patients (0.83% and 
0.29%, respectively; Table II). Some patients had both in-
hospital bleeding and additional bleeding in the 3 months 
after surgery, so that overall, 29 of 4,940 THA patients 
(0.59%) experienced clinically important bleeding, com-
pared with 59 of 5,550 (1.06%) TKA patients. Clinically 
important in-hospital bleeding, albeit rare, was signifi-
cantly more common after TKA than after THA (0.83% vs 
0.48%, respectively; P = .01, Table II). With this level of 
clinically important bleeding in GLORY, it was not pos-
sible to determine which factors were associated with an 
increased risk for bleeding. Blood transfusions were given 
to 57% of THA and 42% of TKA patients at a median vol-
ume of 600 mL (see also Waddell and colleagues12 in this 
supplement for details on blood usage).
The results from GLORY are consistent with those of a 
recent systematic review,13 which included data from 71 
trials, involving 32,433 patients. This review compared dif-
ferent thromboprophylactic regimens in patients undergo-
ing major orthopedic surgery (THA, TKA, or hip-fracture 
surgery). Major bleeding occurred in 632 patients (1.95%) 
receiving thromboprophylaxis, of whom only 118 (0.4%) 
required surgical or medical intervention; only 5 cases of 
fatal bleeding were identified. The most common location 
of bleeding was the wound site, which accounted for 71% 
of major bleeding episodes; 7% of episodes occurred in the 
gastrointestinal tract, and the remainder at other sites.13  
Impact of Thromboprophylaxis on Bleeding Risk
Major or minor bleeding can occur in a significant pro-
portion of patients who are undergoing major orthopedic 
surgery, even in the absence of thromboprophylaxis. For 
example, in a meta-analysis of 52 trials of thrombopro-
phylaxis, involving almost 11,000 THA patients, the total 
incidence of minor and major bleeding in placebo-treated 
patients was 3.0% and 0.6%, respectively.14 
The GLORY population consisted of a large sample 
of THA and TKA patients, of whom almost all (99% 
in both groups) received some form of thrombopro-
phylaxis. Approximately two-thirds of patients in each 
group received low-molecular-weight heparin (LMWH) 
and approximately 30% in each group received warfarin. 
As shown in Table III, the incidence of bleeding, either in 
hospital or at 3 months after discharge, was low in these 
patients (0.8% in LMWH-treated patients; 0.6% in war-
farin-treated patients). Data from randomized controlled 
trials and meta-analyses have shown that prophylactic 
doses of vitamin-K antagonists, low-dose unfractionated 
heparin (UFH), and LMWH are associated with little or no 
increase in the risk of clinically significant bleeding.14,15 In 
the meta-analysis by Muntz and colleagues,13 the relative 
risk of major bleeding with UFH, compared with LMWH, 
was 1.52 (95% CI, 1.04–2.23). In addition, fondaparinux, 
a synthetic pentasaccharide, was also associated with an 
increased risk of major bleeding, compared with LMWH 
(Relative Risk, 1.52; 95% CI, 1.11–2.09).
In GLORY, in-hospital bleeding was significantly less 
common in warfarin-treated patients than in those receiving 
LMWH (0.3% vs 0.7%, respectively; P = .01). This might 
reflect the delayed onset of the anticoagulant effect of war-
farin, as a result of which the therapeutic effect might not 
have been achieved in many patients until after discharge 
from hospital. Furthermore, owing to the nature of the 
GLORY registry, physician perceptions regarding the risk 
of bleeding may have influenced the decision as to which 
drug to give the patient. 
VAsculAr coMplicAtions
Venous Thromboembolism
The GLORY data reflect the incidence of VTE in a real-
world setting, in contrast to those data that are generated 
in the rigorously controlled conditions of clinical trials. 
Thromboprophylactic practices vary widely between hos-
pitals, and they are fully documented in the registry. 
As shown in Table I, DVT (confirmed by venogram or 
ultrasound) was one of the most common in-hospital and 
delayed complications in both THA and TKA patients 
enrolled in GLORY. The incidence of VTE (DVT and PE) 
in different patient subgroups is shown in Table IV. The 
overall incidence of DVT in-hospital and post-discharge 
was higher in TKA patients than in THA patients (2.3% 
vs 1.6%, respectively). In patients undergoing TKA, the 
incidence was higher in women than in men and was 
similar in older (age ≥ 65 years) and younger (age < 65 
years) patients. In THA patients, the incidence of DVT 
was similar irrespective of sex or age. The incidence of 
    5
Table V. In-Hospital and 
Post-Discharge Mortality
    THA TKA
    (n = 6,695) (n = 8,325)
Deaths in hospital   9 (0.1%) 16 (0.2%)
   Deaths attributed to PE in hospital   0   2
Post-discharge deaths within  
      3 months of surgery* 16 (0.3%)   7 (0.1%)
    Deaths attributed to PE post-discharge   1   0
* Median follow-up 3 months, range 1-18 months. Four additional  
TKA deaths occurred at 6-15 months post-surgery.
Abbreviations: PE, pulmonary embolism; THA, total hip arthroplasty;  
TKA, total knee arthroplasty.
Table IV. Incidence of Venous 
Thromboembolism (DVT and PE) According 
to Patient Sex and Age
             DVT             PE  
   THA TKA THA TKA
Total 1.6% 2.3% 0.24% 0.29%
Men  1.4% 1.6% 0.25% 0.32%
Women 1.7% 2.6% 0.25% 0.28%
Age < 65 years 1.4% 2.3% 0.23% 0.47%
Age ≥ 65 years 1.8% 2.2% 0.25% 0.21%
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; THA, 
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PE was 0.2% to 0.3% in all subgroups except in men who 
underwent TKA and TKA patients under 65 years of age, in 
which the incidences of PE were slightly higher at 0.32% 
and 0.47%, respectively.
Similar findings were reported in a review of the epide-
miology of VTE in patients undergoing major orthopedic 
surgery.16 The data from 7 studies of pharmacologic or 
mechanical thromboprophylaxis in patients undergoing 
THA, TKA, or hip-fracture surgery suggest that the inci-
dence of DVT is approximately 2.5% and that the risks of 
nonfatal or fatal PE occurring are approximately 1% and up 
to 0.4%, respectively.16  
A further study has used data from the California Patient 
Discharge Series (a registry of discharge data from all 
nonfederal licensed hospitals in California) to investigate 
the incidence of symptomatic VTE in patients undergoing 
a variety of surgical procedures.17 The incidence of VTE 
at 91 days in patients undergoing THA or TKA was 2.4% 
and 1.7%, respectively, of which 1.8% and 0.8% of cases, 
respectively, occurred after discharge. It should be noted, 
however, that information about the use of thromboprophy-
laxis was not available in this study.
A recent report has described the incidence of PE in 
3,954 patients undergoing THA, TKA, or hip-fracture 
surgery, who were included in a prospective registry in 
Southern Norway between 1989 and 1998.18 All patients 
received thromboprophylaxis with LMWH for about 10 
days until discharge. A total of 50 cases (1.3%) of nonfa-
tal PE were identified. Importantly, the incidence of PE 
remained elevated for at least 2 to 3 months after surgery 
in patients undergoing THA and for several weeks after 
surgery in TKA patients. This persistent risk, despite the 
use of thromboprophylaxis, has been attributed to the fact 
that risk factors for VTE may be present for longer than the 
normal period of thromboprophylaxis. Extended-duration 
thromboprophylaxis, which continued for up to 35 days 
after surgery, has been shown to reduce still further the risk 
of VTE after THA but not TKA.19,20
Mortality Associated With  
Venous Thromboembolism
Pulmonary embolism has been reported to account for 
approximately 10% of in-hospital deaths,21,22 making VTE 
a major cause of mortality. Deaths that occurred either in 
hospital or post-discharge in the GLORY population are 
summarized in Table V. Overall, 25 of 6,695 (0.4%) THA 
patients and 23 of 8,325 (0.3%) TKA patients died in hospital 
or within 3 months after discharge, of whom 3 were believed 
to have died as a result of PE. 
This low mortality rate is in marked contrast to data from 
the Norwegian Arthroplasty Register, which reported a 6% 
incidence of vascular death within 60 days after THA.23 
The mortality rate associated with PE or pulmonary infarc-
tion was 0.92%, and that associated with DVT was 0.28%. 
These higher rates, compared with the current GLORY 
results, may reflect improvements in surgical and prophy-
laxis techniques over the years.
Low rates of cardiac events occurred in the GLORY 
population, with 0.4% and 0.8% of THA and TKA patients, 
respectively, experiencing a cardiac complication.
FunctionAl outcoMes
GLORY used a general health questionnaire, the SF-8 
Health Survey (SF-8), and a disease-specific health ques-
tionnaire, the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) to assess functional out-
comes after THA and TKA. The SF-8 is an alternative form 
of the widely used SF-36 quality-of-life (QOL) questionnaire, 
which uses a single question to measure each of the 8 SF-36 
domains (physical function, social function, role-emotional, 
6   l t t   i  l f t i
Table VI. Functional Outcomes After THA or TKA, Assessed by Means of the WOMAC 
and SF-8 Questionnaires, According to Patient Characteristics
    WOMAC   SF-8 Mental    SF-8 Physical
   n Pre  Post  Diff n Pre  Post   Diff n Pre  Post  Diff
THA  2662    42.7 76.6      33.9  2546 47.0 51.7  4.8 2546 31.4 43.8 12.4
TKA  2987    46.5      72.8 26.3 2802 48.8 51.1  2.2 2802 32.7 42.4     9.8
P value   <.0001  <.0001  <.0001   <.0001    .004   <.0001   <.0001    <.0001  <.0001
Male 2060 48.0 76.7 28.8 1939 50.0 52.6  2.7 1939 33.2 44.3 11.1
Female 3489 42.8 73.3 30.6 3311 46.7 50.6  3.9 3311 31.4 42.5 11.1
P value   <.0001  <.0001    .001   <.0001  <.0001 <.0001   <.0001  <.0001     .94
Age < 65 years 2156 43.2 74.5 31.4 2059 47.8 51.6  3.8 2059 31.7 43.5 11.8
Age ≥ 65 years 3459 45.7 74.6 28.9 3256 48.0 51.2  3.2 3256 32.3 42.8 10.5
P value   <.0001    .92  <.0001     .53    .07    .03     .01    .005   <.0001
Home 3251 45.2 75.6 30.4 3084 48.0 51.7  3.7 3084 32.5 44.1 11.6
Rehabilitation/
   Other 2266 43.9 73.1 29.2 2141 47.9 50.9  3.1 2141 31.4 41.7 10.3
P value     .005  <.0001    .01     .79    .003    .03   <.0001  <.0001  <.0001
Abbreviations: Diff, difference in mean scores; Post, mean 3-months postoperative score; Pre, mean preoperative score; SF-8, SF-8 Health Survey; THA, total hip 
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role-physical, bodily pain, general health, mental health, and 
vitality). The WOMAC is a self-administered questionnaire 
that assesses pain, stiffness, and physical function. Both the 
SF-36 and WOMAC have been shown to be valid tools to 
assess outcomes after THA.24 
Table VI summarizes changes in SF-8 and WOMAC 
scores following THA or TKA in the GLORY popula-
tion. Both measures showed, as expected, marked improve-
ments after surgery. THA patients showed significantly 
lower scores before surgery than TKA patients, indicat-
ing that these patients experienced more pain and disabil-
ity, and scores improved after surgery to a significantly 
(P<.001) greater extent in THA patients than in TKA 
patients. The WOMAC and SF-8 mental scores were sig-
nificantly (P<.0001) lower in women than in men prior 
to and after surgery, although they improved to a signifi-
cantly greater extent in women (P = .0001 for WOMAC; 
P<.0001 for SF-8 mental. Improvements in all scores after 
surgery were significantly lower in older patients (aged ≥ 65
years) than in younger patients, possibly reflecting the impact 
of comorbidity in older patients. Significantly greater improve-
ments were also seen in patients who had been discharged to 
their homes rather than to rehabilitation facilities.
The WOMAC scores that were reported postoperatively 
are similar to those reported at 2 and 3 years after surgery 
in the Swedish National Total Hip Arthroplasty Register (a 
mean score of 74 at both time points).25 This registry is also 
consistent with the GLORY data in that men showed higher 
postoperative QOL scores, as measured by the SF-36 ques-
tionnaire, than women.26 
The finding in GLORY that patients ≥ 65 years showed 
poorer improvements in functional outcomes than younger 
patients is in contrast to a previous study in 454 patients 
undergoing THA or TKA.27 In this study, there were 
no significant differences between the improvements in 
WOMAC and SF-36 scores after surgery in patients aged 
55 to 79 years and in those aged ≥ 80 years. Similarly, the 
finding in the present study that patients who had been dis-
charged to their homes had higher QOL scores than those 
who had been discharged to rehabilitation facilities is at 
variance with those of a previous study involving 96 total 
arthroplasty patients.28 In the latter study, there were no 
significant differences in outcome scores between patients 
who had been discharged to a subacute rehabilitation pro-
gram and those who had been discharged directly to their 
homes with physical therapy follow-up. These differences 
may reflect the impact of sample size: as a result of the 
large number of patients enrolled in GLORY, this study 
can more easily identify patient-related factors affecting 
functional outcomes.
conclusions
Although a variety of complications have been reported to occur 
after THA or TKA, the GLORY data show that the incidence of 
major complications is low. The most common complications 
included reoperations, infections, DVT, and (in THA patients) 
dislocations. It is notable that clinically important bleeding was 
rare in the large sample of THA or TKA patients, essentially all 
of whom were given thromboprophylaxis.
The finding that DVT occurred in up to 1.4% of patients 
enrolled in GLORY shows that VTE remains an important 
potential complication of THA and TKA, despite the wide-
spread use of thromboprophylaxis. This problem may be, at 
least partly, overcome by extending the duration of prophy-
laxis for up to 35 days after surgery, as has been shown to 
be effective in THA patients.19,20 
The data from GLORY show that the functional out-
comes after THA or TKA may depend on the patient’s 
characteristics. Although total arthroplasty can markedly 
improve patients’ functioning and general well-being, the 
greatest benefits seem to be achieved in younger patients 
and in patients who have been discharged directly to 
their homes. 
In conclusion, GLORY provides contemporary data on 
outcomes that occur after THA or TKA; these data are 
derived from a global, real-world setting that clinical tri-
als are unable to reproduce as the inclusion and exclusion 
criteria are limiting. GLORY has been able to recruit a large 
and diverse patient population, and hence it was able to 
identify factors affecting outcomes that may not be appar-
ent in clinical trials. It is notable, however, that the physi-
cians in GLORY prescribe aspirin for VTE prophylaxis less 
frequently than has been shown in other studies.29
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